Dyne Therapeutics, Inc. (DYN) Payables and obligations
- Other obligations · latest quarter (USD): Value (m); Formula and calculation Total liabilities − borrowing debt − payables − total deferred revenue. Includes accruals, taxes, leases and other obligations; excludes the separately shown balances. Period ending 2026-06-30..
- Payables · latest quarter (USD): Value $12.15M; Formula and calculation Amounts owed to suppliers, reported accounts payable. Period ending 2026-06-30..
- Deferred revenue · latest quarter (USD): Value (m); Formula and calculation Current and noncurrent customer contract obligations; payments received before revenue is earned. Period ending 2026-06-30..
- Other obligations · due within 1 year (USD): Value (m); Formula and calculation Reported other current liabilities. Excludes separately reported debt, payables and current deferred revenue. The saved current-quarter facts do not separately disclose taxes, payroll, leases or accruals. Period ending 2026-06-30..
Payables and obligations
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Other obligations · latest quarter (USD) | (m) | Total liabilities − borrowing debt − payables − total deferred revenue. Includes accruals, taxes, leases and other obligations; excludes the separately shown balances. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Payables · latest quarter (USD) | $12.15M | Amounts owed to suppliers, reported accounts payable. Period ending 2026-06-30. Reported amount: $12.15M |
| Deferred revenue · latest quarter (USD) | (m) | Current and noncurrent customer contract obligations; payments received before revenue is earned. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Other obligations · due within 1 year (USD) | (m) | Reported other current liabilities. Excludes separately reported debt, payables and current deferred revenue. The saved current-quarter facts do not separately disclose taxes, payroll, leases or accruals. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Other obligations · due after 1 year (USD) | (m) | Reported other noncurrent liabilities minus the noncurrent deferred revenue they include (total customer contract obligations − current portion); a separately reported noncurrent deferred revenue line is not deducted. The saved current-quarter facts do not separately disclose taxes, leases or other accruals. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Total reported obligations | 291.86M USD | Liabilities |
| Borrowing debt | (m) | Long-term Debt, Excluding Current Maturities |
| Amounts owed to suppliers | 12.15M USD | Accounts Payable, Current |
| Total deferred revenue | (m) | |
| Deferred revenue due within one year | (m) | |
| Deferred revenue due after one year | (m) | |
| Reported other obligations due within one year | (m) | |
| Reported other noncurrent obligations | (m) | |
| Deferred revenue included in other noncurrent obligations | (m) |
Other obligations breakdown
- Other obligations · due within 1 year (USD)
- (m)
- Other obligations · due after 1 year (USD)
- (m)
Bonds and commercial paper are already included in Total debt. Other obligations include taxes, accrued expenses and operating/finance leases. Category amounts below are the issuer’s own tagged balances at the same quarter end; untagged categories are not shown.
| Category | Quarter ending 2026-06-30 |
|---|---|
| Operating lease obligations | $19.87M |
These categories are parts of the combined obligations, not additional deductions.
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Other obligations | Payables | Deferred revenue | Short-term obligations | Long-term obligations | Total reported obligations (USD) | Borrowing debt (USD) | Deferred revenue due within one year (USD) | Deferred revenue due after one year (USD) | Reported other noncurrent obligations (USD) | Deferred revenue included in other noncurrent obligations (USD) |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | (m) | $12.15M | (m) | (m) | (m) | $291.86M | (m) | (m) | (m) | (m) | (m) |
| 2026-03-31 | (m) | $10.78M | (m) | (m) | (m) | $214.90M | (m) | (m) | (m) | (m) | (m) |
| 2025-12-31 | (m) | $8.08M | (m) | (m) | (m) | $214.83M | (m) | (m) | (m) | (m) | (m) |
| 2025-09-30 | (m) | $12.06M | (m) | (m) | (m) | $175.28M | (m) | (m) | (m) | (m) | (m) |
| 2025-06-30 | (m) | $14.02M | (m) | (m) | (m) | $157.55M | (m) | (m) | (m) | (m) | (m) |
| 2025-03-31 | (m) | $7.02M | (m) | (m) | (m) | $52.10M | (m) | (m) | (m) | (m) | (m) |
| 2024-12-31 | (m) | $6.56M | (m) | (m) | (m) | $61.40M | (m) | (m) | (m) | (m) | (m) |
| 2024-09-30 | (m) | $6.16M | (m) | (m) | (m) | $63.30M | (m) | (m) | (m) | (m) | (m) |
| 2024-06-30 | (m) | $1.89M | (m) | (m) | (m) | $50.69M | (m) | (m) | (m) | (m) | (m) |
| 2024-03-31 | (m) | $7.21M | (m) | (m) | (m) | $44.22M | (m) | (m) | (m) | (m) | (m) |
| 2023-12-31 | (m) | $22.94M | (m) | (m) | (m) | $73.79M | (m) | (m) | (m) | (m) | (m) |
| 2023-09-30 | (m) | $3.55M | (m) | (m) | (m) | $53.21M | (m) | (m) | (m) | (m) | (m) |
| 2023-06-30 | (m) | $2.72M | (m) | (m) | (m) | $44.54M | (m) | (m) | (m) | (m) | (m) |
| 2023-03-31 | (m) | $8.77M | (m) | (m) | (m) | $46.71M | (m) | (m) | (m) | (m) | (m) |
| 2022-12-31 | (m) | $5.26M | (m) | (m) | (m) | $53.96M | (m) | (m) | (m) | (m) | (m) |
| 2022-09-30 | (m) | $919.00K | (m) | (m) | (m) | $49.94M | (m) | (m) | (m) | (m) | (m) |
| 2022-06-30 | (m) | $6.97M | (m) | (m) | (m) | $52.97M | (m) | (m) | (m) | (m) | (m) |
| 2022-03-31 | (m) | $5.19M | (m) | (m) | (m) | $51.30M | (m) | (m) | (m) | (m) | (m) |
| 2021-12-31 | (m) | $4.03M | (m) | (m) | (m) | $57.47M | (m) | (m) | (m) | (m) | (m) |
| 2021-09-30 | (m) | $7.09M | (m) | (m) | (m) | $52.76M | (m) | (m) | (m) | (m) | (m) |
| 2021-06-30 | (m) | $5.65M | (m) | (m) | (m) | $14.55M | (m) | (m) | (m) | (m) | (m) |
| 2021-03-31 | (m) | $5.76M | (m) | (m) | (m) | $13.45M | (m) | (m) | (m) | (m) | (m) |
| 2020-12-31 | (m) | $3.44M | (m) | (m) | (m) | $10.97M | (m) | (m) | (m) | (m) | (m) |
| 2020-09-30 | (m) | $1.49M | (m) | (m) | (m) | $14.63M | (m) | (m) | (m) | (m) | (m) |
| 2019-12-31 | (m) | $1.26M | (m) | (m) | (m) | $2.40M | (m) | (m) | (m) | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Arcus Biosciences, Inc. (RCUS) | United States | $3.188B | -8.52 |
| Arcutis Biotherapeutics, Inc. (ARQT) | United States | $3.303B | 115.47 |
| Enliven Therapeutics, Inc. (ELVN) | United States | $3.307B | -35.07 |
| Amylyx Pharmaceuticals, Inc. (AMLX) | United States | $3.361B | -13.15 |
| PRECIGEN, INC. (PGEN) | United States | $2.757B | -12.94 |
| NewAmsterdam Pharma Co N.V. (NAMS) | $2.719B | -15.37 | |
| MBX Biosciences, Inc. (MBX) | United States | $2.664B | -25.36 |
| IDEAYA Biosciences, Inc. (IDYA) | United States | $3.540B | -20.52 |
| Organon & Co. (OGN) | United States | $3.603B | 17.03 |
| Disc Medicine, Inc. (IRON) | United States | $2.553B | -11.40 |